[1]乔巧,徐静,王建,等.艾塞那肽对超重/肥胖2型糖尿病患者内脏脂肪及早期肾损伤的影响[J].第三军医大学学报,2018,40(20):1883-1888.
 QIAO Qiao,XU Jing,WANG Jian,et al.Effect of exenatide treatment on visceral fat and early renal injury in overweight/obese T2DM patients[J].J Third Mil Med Univ,2018,40(20):1883-1888.
点击复制

艾塞那肽对超重/肥胖2型糖尿病患者内脏脂肪及早期肾损伤的影响(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第20期
页码:
1883-1888
栏目:
临床医学
出版日期:
2018-10-30

文章信息/Info

Title:
Effect of exenatide treatment on visceral fat and early renal injury in overweight/obese T2DM patients
作者:
乔巧徐静王建郑宏庭童强白倩袁媛
陆军军医大学(第三军医大学)第二附属医院:内分泌科,营养科
Author(s):
QIAO Qiao XU Jing WANG Jian ZHENG Hongting TONG Qiang BAI Qian YUAN Yuan

Department of Endocrinology, Department of Nutriology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
 

关键词:
艾塞那肽糖尿病肥胖微量白蛋白尿内脏脂肪面积
Keywords:
exenatide type 2 diabetes mellitus obesity microalbuminuria visceral fat area  
分类号:
R587.1;R589.2;R977.15
文献标志码:
A
摘要:

目的    探讨艾塞那肽对超重/肥胖的2型糖尿病(type 2 diabetes mellitus,T2DM)患者的微量白蛋白尿(microalbuminuria,MAU)排泄及与内脏脂肪面积(visceral fat area,VFA)、体质指数(body mass index,BMI)、腰臀比(waist-to-hip ratio,WHR)的关系及影响。方法    收集本科2015年1月至2016年6月就诊的符合标准的超重/肥胖的2型糖尿病患者76例,按简单随机化原则分成两组,在原口服降糖方案血糖控制不佳基础上,艾塞那肽组接受艾塞那肽注射液皮下注射,每日2次,对照组采用甘精胰岛素,每日1次,整个治疗共计24周。观察两组患者治疗前后MAU、VFA、BMI、WHR、空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(glycated hemoglobin,HbA1c)的变化,并进行相关分析。结果艾塞那肽组患者在治疗12周和24周后的MAU、VFA、BMI、WHR、FBG、HbA1c较治疗前明显下降(P<0.05),而对照组仅有BMI、FBG和HbA1c呈现明显下降(P<0.05)。艾塞那肽组VFA、BMI、WHR、MAU的变化与FBG、HbA1c的变化呈显著正相关(P<0.05)。结论   艾塞那肽可显著降低超重/肥胖的2型糖尿病患者的MAU排泄、血糖和体脂水平,且MAU排泄下降同VFA、BMI、WHR、血糖的降低密切相关。

Abstract:

Objective    To investigate the relationship and effect of exenatide on microalbuminuria (MAU), visceral fat area (VFA), body mass index (BMI), and waist-to-hip ratio (WHR) in overweight/obese patients with type 2 diabetes mellitus (T2DM). Methods     A total of 77 overweight/obese T2DM patients who met our criteria and admitted in our hospital from January 2015 to June 2016 were enrolled in this study. They were randomly divided into exenatide group and control group. Since their poor glycemic control by original oral hypoglycemic protocol, exenatide injection was given subcutaneously to the former group twice a day, and insulin glargine injection to the latter group, once a day for a total of 24 weeks. The changes of MAU, VFA, BMI, WHR, fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were observed before and after treatment in the 2 groups, and the correlation analysis was made. Results    The levels of MAU, VFA, BMI, WHR, PBG and HbA1c were significantly decreased in the exenatide group after 12 and 24 weeks’ treatment (P<0.05). In the exenatide group, the changes of MAU, VFA, BMI and WHR were positively correlated with those of PBG and HbA1c (P<0.05), while such differences were only found in the levels of BMI, PBG and HbA1c in the control group (P<0.05). In the exenatide group, the changes of MAU, VFA, BMI and WHR were positively correlated with those of PBG and HbA1c (P<0.05). Conclusion     Exenatide obviously reduces MAU, obesity and blood glucose in overweight/obese T2DM patients, and the excretion of MAU is closely associated with the decreases of VFA,WHR, BMI and blood glucose.

参考文献/References:

[1]XU Y, WANG L, HE J, et al. 2010 China Noncommunicable Disease Surveillance Group.Prevalence and eontrol of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959. DOI: 10.1001/jama.2013.168118.
[2]DE BOER I H, RUE T C, HALL Y N et al. Temporal trends in the prevalence of diabetic kidney disease in the United States [J]. JAMA, 2011, 305(24): 2532-2539. DOI: 10.1001/jama.2011.861.
[3]中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识(2014年版)[J]. 中国糖尿病杂志, 2014, 6(11): 792-801. DOI: 10.3969/j.issn.10088296.201505.
The microvascular complications group of Chinese Diabetes Society, Chinese Medical Association. Expert consensus on the prevention and control of diabetic nephropathy (2014)[J].  Chin J Diabetes Mellitus, 2014, 6(11): 792-801. DOI: 10.3969/j.issn.10088296.201505.
[4]TAPP R J, SHAW J E, ZIMMET P Z, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) [J]. Am J Kidney Dis, 2004, 44(5): 792-798. DOI: 10.1053/j.ajkd.2004.07.006.
[5]HU J, YANG S, ZHANG A, et al. Abdominal obesity is more closely associated with diabetic kidney disease than general obesity[J]. Diabetes Care, 2016, 39(10): e179-e180. DOI: 10.2337/dc161025.
[6]吴敏, 刘芳, 付平. 胰高血糖素样肽1与糖尿病肾病[J]. 中华肾病杂志, 2011, 27(12): 941-944. DOI: 10.3760/cma.j.issn.10017097.2011.12.018.
WU M, LIU F, FU P. Glucagon like peptide 1 and diabetic nephropathy[J]. Chin J Nephrol, 2011, 27(12): 941-944. DOI: 10.3760/cma.j.issn.10017097.2011.12.018.
[7]TONG Q, WANG H, GUAN L Z, et al. Clinical effects of exenatide in treatment of type 2 diabetes and on expression of Cpeptide[J]. Third Mil Med Univ, 2014, 36(15): 1604-1606.DOI: 10.16016/j.10005404.2014.15.015.
[8]KODERA R, SHIKATA K, KATAOKA H, et al. Glucagonlike peptide1 receptor agonist ameliorates renal injury through its antiinflammatory action without lowering blood glucose level in a rat model of type diabetes[J]. Diabetologiam, 2011, 54(5): 965-978. DOI: 10.1007/s001250102028x.
[9]HOU X, LU J, WENG J, et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey[J]. PLoS ONE, 2013, 8(3): e57319. DOI: 10.1371/journal.pone.0057319.
[10]KANG S H,CHO K H, PARK J W, et al. Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multifrequency bioimpedance[J]. Kidney Blood Press Res, 2015, 40(3): 223-230. DOI: 10.1159/000368498.
[11]BU J, FENG Q, RAN J, et al. Visceral fat mass is always, but adipokines (adiponectin and resistin) are diversely associated with insulin resistance in Chinese type 2 diabetic and normoglycemic subjects[J]. Diabetes Res Clin Pract, 2012, 96(2): 163-169. DOI: 10.1016/j.diabres.2011.12.014.
[12]SHEPHERD J, KASTELEIN J J, BITTNER V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study[J]. Clin J Am Soc Nephrol, 2007, 2(6): 1131-1139. DOI: 10.2215/CJN.04371206.
[13]GOSMANOV A R, GOSMANOVA E O. Longterm renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the DCCT/EDIC cohort[J]. Arch Intern Med, 2011, 171(17): 1596. DOI: 10.1001/archinternmed.2011.413.
[14] DOUNOUSI E, DUNI A, LEIVADITIS K, et al. Improvements in the management of diabetic nephropathy[J]. Rev Diabet Stud, 2015, 12(1/2): 119-133. DOI: 10.1900/RDS.2015.12.119.
[15]UK Prospective Diabetes Study (UKPDS) Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)[J]. Lancet, 1998, 352(9131): 837-853. DOI: 10.1016/S01406736(98)070196.
[16]BLONDE L, PENCEK R, MACCONELL L.Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2015, 14: 12. DOI: 10.1186/s1293301401712.
[17]JAMESON K,D’OCA K,LEIGH P, et al. Adherence to NICE guidance on glucagonlike peptide1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink[J]. Curr Med Res Opin, 2016, 32(1): 49-60. DOI: 10.1185/03007995.2015.1101372.
[18]SAIKI A, NAGAYAMA D, OHHIRA M, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy[J]. Int J Obes (Lond) 2005, 29(9): 1115-1120. DOI: 10.1038/sj.ijo.0803009.
[19]FORNONI A, IJAZ A, TEJADA T, et al. Role of inflammation in diabetic nephropathy[J]. Curr Diabetes Rev, 2008, 4(1): 10-17. DOI: 10.2174/157339908783502361.
[20]ISHIBASHI Y, NISHINO Y, MATSUI T, et al. Glucagonlike peptide1 suppresses advanced glycation end productinduced monocyte chemoattractant protein1 expression in mesangial cells by reducing advanced glycation end product receptor level[J]. Metabolism, 2011, 60(9): 1271-1277. DOI: 10.1016/j.metabol.2011.01.010.
[21]OESEBURG H, DE BOER R A, BUIKEMA H, et al. Glucagonlike peptide 1 prevents reactive oxygen speciesinduced endothelial cell senescence through the activation of protein kinase A [J]. Arterioscler Thromb Vasc Biol, 2010, 30(7): 1407-1414. DOI: 10.1161/ATVBAHA.110.206425.

相似文献/References:

[1]牟海刚,古平.莱姆病伴直立性低血压误诊为糖尿病心血管自主神经病1例[J].第三军医大学学报,2012,34(15):1542.
[2]周厚地,童强,段炼,等.胃大部切除术致糖尿病患者反复低血糖1例[J].第三军医大学学报,2012,34(17):1753.
[3]吴艳,王毅,曾绍凡,等.老年2型糖尿病瘦素、骨密度变化及相关因素的研究[J].第三军医大学学报,2007,29(22):2188.
 WU Yan,WANG Yi,ZENG Shao-fan,et al.Bone density, leptin level and other related factors in elder patients with type 2 diabetes[J].J Third Mil Med Univ,2007,29(20):2188.
[4]李志勤.饮食护理干预对老年糖尿病患者血糖和糖化血红蛋白水平的影响[J].第三军医大学学报,2012,34(20):2130.
[5]徐灵莉,邓本敏,唐玲,等.护理风险管理能有效提高糖尿病合并恶性肿瘤患者的化疗疗效[J].第三军医大学学报,2013,35(04):351.
 Xu Lingli,Deng Benmin,Tang Ling,et al.Risk management of nursing improves chemotherapy efficiency for diabetic patients with malignant tumor[J].J Third Mil Med Univ,2013,35(20):351.
[6]魏平.糖尿病治疗的新趋势及相关热点追踪[J].第三军医大学学报,2012,34(23):2435.
[7]李明秀,王建,樊荣,等.癌症合并糖尿病患者住院期间的营养治疗[J].第三军医大学学报,2007,29(21):2079.
[8]高原,肖谦,赵柯湘,等.替米沙坦对糖尿病大鼠认知功能的保护作用[J].第三军医大学学报,2007,29(15):1514.
 GAO Yuan,XIAO Qian,ZHAO Ke-Xiang,et al.The study of the protection of telmisartan on the cognitive function in diabetic rats[J].J Third Mil Med Univ,2007,29(20):1514.
[9]范伟,杨妤欣,陈隽,等.糖尿病大鼠早期骨微结构改变及其BMP-2基因的表达[J].第三军医大学学报,2007,29(11):1053.
 FAN Wei,YANG Yu-xin,CHEN Juan,et al.Bone microstructure changes and bone BMP-2 expression in rats at early period of diabetes[J].J Third Mil Med Univ,2007,29(20):1053.
[10]杨光玉,卿尚兰,陈英.糖尿病患者根管治疗中疼痛有关因素的临床研究[J].第三军医大学学报,2007,29(10):982.
 YANG Guang-yu,QING Shang-lan,CHEN Ying.Correlation of diabetes mellitus and endodontic interappointment pain[J].J Third Mil Med Univ,2007,29(20):982.

更新日期/Last Update: 2018-11-01